- InterView
- Otrivin package made user-friendly for pharmacist & patient
- by Eo, Yun-Ho Jun 13, 2022 05:55am
- One strong perception of allergic rhinitis is that its symptoms worsen during the change of seasons and then decrease in summer. However, the large temperature difference between indoors and outdoors in summer due to excessive operation of air conditioners can dry out the mucous membranes and further weaken the immune system. Topical deco
- InterView
- “Allowing safe use of JAK inhibitors over restrictions"
- by Eo, Yun-Ho May 26, 2022 05:56am
- Nowadays, safety is as important as a drug’s efficacy. In particular, reaffirming the safety of drugs that require long-term administration post-approval is essential. JAK inhibitors, which have entered the market as an oral option to treat various autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis, have been em
- InterView
- We are making all efforts to reimburse ‘Vyndamax’
- by Eo, Yun-Ho Apr 21, 2022 06:03am
- Rare disease patients suffer more due to the 'rarity' of their condition. Due to the small number of affected patients, even drugs that are already available cannot be easily listed for reimbursement due to difficulty in demonstrating cost-effectiveness or predicting their fiscal impact on the NHI budget. Rare diseases are diseases that
- InterView
- "Will make R&D partnerships, introduce new drugs in Korea"
- by Apr 14, 2022 05:56am
- The China Shanghai-based Antengene has started its activities in earnest in the domestic pharmaceutical market. Marking its start with Xpovio (selinexor), a blood cancer drug that was approved in July last year, the company aims to introduce more new drugs in cancers with high unmet needs. Antengene is an anticancer drug developer that has r
- InterView
- Sanofi introduces digital solutions for customers & patients
- by Eo, Yun-Ho Feb 22, 2022 05:55am
- The recent management trend of global big perm is choice and concentration. The number of companies strengthening and separating specialized areas through mergers and spraying has increased significantly. Sanofi Group, a French pharmaceutical company, was originally specialized in diabetes drugs such as insulin, but it absorbed Genzyme, a
- InterView
- Era of ₩30 bil novel homegrown drug Suganon begins now
- by Feb 3, 2022 05:57am
- Annual sales of the 26th homegrown new drug ‘Suganon (evogliptin)’ family that was developed by Dong-A ST has reached &8361;30 billion 5 years into its release. During an interview with Dailypharm, Sung-Woo Lee, the GPM who oversees the marketing of Suganon, said, “Market share of Suganon has been steadily increasing due to its superio
- InterView
- There shouldn't be any patients who can't receive new drugs
- by Eo, Yun-Ho Jan 5, 2022 05:59am
- Global pharmaceutical companies, which can be said to be the mainstay of the supply of new drugs. The KRPIA, which represents these companies, is also raising expectations in 2022. Multinational pharmaceutical companies' attention is more focused on the "appropriate value of new drugs" than ever before. With the advent of the so-called "high-
- InterView
- Ibrance can be used regardless of underlying condition in BC
- by Dec 24, 2021 05:48am
- It has been 5 years since Pfizer’s breast cancer treatment ‘Ibrance (Palbociclib)’ was introduced to the Korean market. As the first cyclin-dependent kinase 4/6 (CDF 4/6) inhibitor, the drug had innovated the treatment paradigm for patients with metastatic and recurrent hormone receptor-positive (HR-positive) and human epidermal growth fa
- InterView
- KYMRIAH, a good but expensive medicine
- by Eo, Yun-Ho Nov 4, 2021 05:56am
- The cost of a single injection is 500 million won, but the era has come when cancer can be expected to be cured with that "once." Ultra-high-priced, high-tech new drugs are already approaching us. Kymriah (Tisagencleucel), a CAR-T treatment called dream anticancer, is the new drug. Kymriah obtained approval from the MFDS in March as the fi
- InterView
- Patients with severe diseases don't really like Mooncare
- by Lee, Jeong-Hwan Oct 28, 2021 05:59am
- Health insurance authorities should recognize that as universal health and welfare increases the coverage of mild diseases, the access to drugs for severely rare and intractable diseases is greatly reduced. It is nonsense that policies to strengthen coverage such as herbal medicine benefits are implemented without economic evaluation today, w
